Latest Pharma and Biotech News
Pharmaceutical
5 February 2026 The US Federal Trade Commission has hailed what it calls a ‘landmark settlement’ with one of the nation’s largest pharmacy benefit managers (PBMs), Express Scripts, and its affiliated entities.
Today's issue
Refine search
article
US biotech Eikon Therapeutics has raised about $381 million in the largest biotech IPO of the year so far, but the market’s first reaction was cautious. Shares fell nearly 17% on their first day of trading, closing at $15. 6 February 2026
Biotechnology
Chinese biotech Kelun-Biotech has won a new approval from China’s National Medical Products Administration for sac-TMT (sacituzumab tirumotecan), a TROP2-directed antibody-drug conjugate. 6 February 2026
Biotechnology
Pfizer today announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review for the company’s supplemental Biologics License Application (sBLA) for Hympavzi (marstacimab) to expand the approved indication to include the treatment of hemophilia A or B patients 6 years and older with inhibitors, and pediatric patients (ages 6 to 11) with hemophilia A or B without inhibitors. 6 February 2026
Biotechnology
US biotech company Biogen today reported fourth quarter 2025 results topping the market’s revenue expectations, but sales fell by 7.1% year on year to $2.28 billion. Biogen’s share were up 4.3% at $192.97 in early trading. 6 February 2026
Biotechnology
Swiss biotech firm Idorsia today announced the design of its US Food and Drug Administration (FDA)-agreed Phase III registration program for lucerastat in Fabry disease. 6 February 2026
Pharmaceutical
M&A activity in the pharmaceutical and biotechnology sectors in January was active but skewed toward mid-size strategic transactions rather than blockbuster takeovers. 6 February 2026
Biotechnology
Following on from a host of successful or planned initial public offerings (IPOs) in biotech so far this year, another firm has lined up a listing. 6 February 2026
Pharmaceutical
Having been pushed back from an expected January launch, the US government's TrumpRx website - intended to offer discounts on certain prescription drugs for cash-pay patients - made its debut late on Thursday. 6 February 2026
Biotechnology
Privately-held San Diego biotech ADARx Pharmaceuticals announced the appointment of Dr Donald Fong as chief medical officer (CMO) to lead the advancement of its clinical-stage pipeline. 6 February 2026
Biotechnology
In the UK, local authorities have agreed a partnership with specialist developer Prologis to support the next stage of growth at Cambridge Biomedical Campus, one of Europe’s biggest life sciences clusters. 6 February 2026
Generics
Danish drugmaker's Novo Nordisk’s shares fell more than 8% on Thursday after Hims & Hers announced that it would be releasing a compounded version of its oral GLP-1 agonist Wegovy (semaglutide), a weight-loss pill with a $49-a-month introductory price. 6 February 2026
Pharmaceutical
Swedish life sciences investor Karolinska Development says its portfolio company SVF Vaccines has agreed a reverse acquisition with Novakand Pharma, a move that would put SVF into a publicly listed vehicle. 6 February 2026
Pharmaceutical
German drugmaker Bayer has revealed positive late-stage results for its investigational once-daily oral anticoagulant asundexian. 6 February 2026
Biotechnology
California-based Braveheart Bio, a biotech developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and related cardiovascular conditions, has announced that Marc Evanchik has been promoted to chief scientific officer (CSO). 5 February 2026
Pharmaceutical
German family-owned pain specialist Grünenthal has entered into a licensing agreement whereby Canada-based Apotex will have the exclusive Canadian rights to Nebido (testosterone undecanoate), a long-acting injectable therapy indicated for the treatment of male hypogonadism (testosterone deficiency). 5 February 2026
Pharmaceutical
The global proteomics market was valued at $29.9 billion in 2025 and is forecast to grow to $58.7 billion by 2031, according to Mordor Intelligence. The firm estimates a compound annual growth rate of nearly 12% between 2026 and 2031. 5 February 2026
Pharmaceutical
Russia faces a significant increase in the number of cancelled tenders during drug procurements for state needs, which is mainly due to unfavorable conditions for suppliers and low prices, reports The Pharma Letter’s local correspondent. 5 February 2026
Pharmaceutical
US pharma major Bristol Myers Squibb reported fourth-quarter 2025 revenues of $12.5 billion, up 1%, with GAAP earnings per share of $0.53 and non-GAAP EPS of $1.26. Full-year revenues were $48.2 billion, essentially flat, while non-GAAP EPS rose to $6.15. 5 February 2026
Biotechnology
A study funded by Israeli pharma and generics player Teva has contributed to the growing body of real-world evidence (RWE) supporting Ajovy (fremanezumab) as an effective migraine-preventive therapy in patients with chronic migraine (CM) and episodic migraine (EM). 5 February 2026
Biotechnology
California, USA-based Coherus Oncology has entered into a clinical supply agreement with JUS healthcare giant Johnson & Johnson to evaluate tagmokitug (CHS-114). 5 February 2026
All news
Biotechnology
China is making significant strides in CAR-T innovation. Recently, Chongqing Precision Biotech received approval for Priligy (priscabtagene autoleucel) to treat pediatric and adolescent patients aged 3 to 21 years with CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). 9 December 2025
Biotechnology
Roche has unveiled a fresh wave of data for Lunsumio (mosunetuzumab), underscoring the Swiss pharma major’s ambition to move its CD20xCD3 bispecific earlier in follicular and large B-cell lymphomas. 9 December 2025
Generics
The US Association for Accessible Medicines (AAM) the leading trade association for generic and biosimilar manufacturers, applauds and supports The Skinny Labels, Big Savings Act, which was introduced yesterday in the US House of Representatives. 9 December 2025
Biotechnology
The cell and gene therapy (CGT) sector is undergoing a transition as companies navigate a more selective and strategy-driven funding landscape, according to an analysis by the pharma strategic intelligence team at and pharma analytics company. GlobalData. 9 December 2025
Pharmaceutical
Italian pharma major Recordati’s rare diseases subsidiary announced the presentation of new data detailing advances in the understanding of Castleman disease (CD), a group of rare immune system disorders characterized by abnormal lymph node enlargement and systemic inflammatory symptoms that can be potentially life-threatening. In a series of poster presentations at the 67th American Society of Hematology Annual Meeting (ASH) Annual Meeting in Orlando, Florida. 9 December 2025
Biotechnology
Gene therapy company uniQure last week received final minutes from the US Food and Drug Administration (FDA) regarding its pre-Biologics License Application (BLA) meeting held in late October to discuss the company’s application for AMT-130 in Huntington’s disease (HD). 8 December 2025
Biotechnology
Danish biotech Genmab has announced primary data from the pivotal Phase III EPCORE FL-1 study of fixed duration Epkinly (epcoritamab-bysp) alongside rituximab and lenalidomide (Epkinly + R2) in adults with relapsed or refractory (R/R) follicular lymphoma (FL). 8 December 2025
Biotechnology
US rare disease drug developer Mirum Pharmaceuticals today announced its entry into a definitive agreement to acquire Bluejay Therapeutics, a privately held biotechnology company focused on viral and liver diseases. 8 December 2025
Biotechnology
Shanghai-based biotech OTR Therapeutics has emerged from stealth and announced the successful completion of a $100 million Series A financing closed in June 2025. 8 December 2025
Biotechnology
Shares of US clinical-stage biotech Kymera Therapeutic leapt almost 33% to $88.48 pre-market, as it announced compelling early results for its first-in-class oral STAT 6 degrade KT-621. 8 December 2025
Biotechnology
During Blood Cancer Awareness Month, Guy Martin, news editor at The Pharma Letter, sat down with Dr Hanbali to discuss his experiences treating patients with CAR T-cell therapy in the Middle East. 8 December 2025
Biotechnology
French biotech start-up SeaBeLife, which is developing innovative drug candidates intended to block cellular necrosis, has signed a joint development agreement with Unither Pharmaceuticals, a French pharmaceutical CDMO with an international footprint, specialized in the development and manufacture of sterile single doses. 8 December 2025
Biotechnology
Gilead Sciences subsidiary Kite and its partner Arcellx have announced new positive data from the pivotal iMMagine-1 Phase II study of anitocabtagene autoleucel (anito-cel). 8 December 2025
Biotechnology
Swiss incubator Xlife Sciences today announced that Mexico-based Grupo Landsteiner has signed a binding framework to acquire 12 of Xlife Sciences’ advanced biotech, medtech and digital health projects for a total of $450 million, payable in Landsteiner shares. 8 December 2025
Pharmaceutical
Belgium’s UCB has presented positive efficacy and safety results from the GEMZ Phase III study investigating adjunctive Fintepla (fenfluramine) in children and adults with CDKL5 deficiency disorder (CDD) at the American Epilepsy Society (AES) meeting, Atlanta, USA. 8 December 2025
Pharmaceutical
The release of Phase III Stage 1 data for gotistobart (BNT316/ONC-392) at NACLC 2025 marks one of the most significant developments in CTLA-4–targeted therapy in recent years. 8 December 2025
Biotechnology
German biotech BioNTech and USA-based OncoC4 yesterday presented data from the non-pivotal dose-confirmation stage of the global randomized Phase III trial PRESERVE-003 for gotistobart (also known as BNT316 or ONC-392), a tumor microenvironment-selective regulatory T cell (Treg) depletion candidate, targeting CTLA-4 in patients with metastatic squamous non-small cell lung cancer (sqNSCLC). 8 December 2025
Biotechnology
Belgian biotech Galapagos reported new Phase II results for its fresh, memory-enriched CAR T candidate GLPG5101 in relapsed or refractory mantle cell lymphoma at the American Society of Hematology meeting. The therapy maintained a seven-day vein-to-vein time for almost all patients, supporting rapid treatment delivery. 8 December 2025
Biotechnology
Dutch biotech Pan Cancer T has raised 10 million euros ($11 million) to advance its lead cell therapy, PCT1:CO-STIM, into a first-in-human trial for women with triple-negative breast cancer. The round combines 5 million euros from existing investors and a 5 million euro government-backed loan. 8 December 2025
Biotechnology
A German court has ordered Merck & Co to halt launch preparations for its new subcutaneous version of Keytruda (pembrolizumab) in the country, handing Halozyme Therapeutics an early advantage in a widening patent dispute over injectable delivery technology. The ruling follows Halozyme’s request for urgent relief. 8 December 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze